Skip to content

Patientory Wallet launches GLP-1 Telehealth, secures more funding

Patientory Wallet launches GLP-1 Telehealth, secures more funding

On February 7, healthcare data startup Patientory announced the introduction of its latest telehealth service focused on weight loss, which includes GLP-1 prescriptions like Semaglutide. 

This launch reflects Patientory’s commitment to advancing the democratization of health data while concurrently shaping the future landscape of healthcare within Web3.

Patientory, recognized for its decentralized applications, including the consumer Digital Health Data Wallet, specializes in facilitating clinical trial recruitment utilizing individual data. 

The company incentivizes individuals to adopt healthy habits and contribute their health data to clinical research by offering reward-based payments, per the information shared with Finbold.

General health need for Patientory

Amidst the pressing issue of escalating adult obesity rates in the United States, Patientory introduces a novel service offering accessible and personalized weight loss solutions to a vast population. Interested individuals can utilize the Patientory Health Data Wallet to ascertain their Body Mass Index (BMI) and eligibility for a Semaglutide GLP-1 prescription.

Upon meeting the eligibility criteria, Patientory’s weight-loss program extends a tailored prescription plan to users. Supervised by accredited physicians, individuals receive personalized guidance, medication, and assistance. 

The initial package for the first month comprises a medical telehealth consultation, prescription, a one-month provision of Semaglutide medication, and shipping services.

What is Semaglutide?

Semaglutide belongs to a category of medications called glucagon-like peptide-1 (GLP-1) receptor agonists. These medications emulate the actions of the GLP-1 hormone, which is naturally released following food intake and encourages insulin secretion to lower blood glucose levels. Clinical trials have evidenced the effectiveness of Semaglutide in promoting weight loss.

Kwamena Aidoo, co-founder and managing partner of Corridor Ventures, said:

“Connecting wearable devices and electronic health records data has the potential to transform clinical research insights and evolve the way health and wellness care is administered across the globe. Patientory sits at the forefront of this movement. When you think about this in the broader context of our rapidly changing technological landscape, it is hard not to get excited.”

Patientory has been recently designated as a “2024 Health Equity Business Accelerator Participant” by Blue Cross Blue Shield of Massachusetts (BCBSMa). Additionally, the company has secured early-stage funding from VC firm Corridor Ventures, further augmenting their total in new seed investments to over $325,000.

Best Crypto Exchange for Intermediate Traders and Investors

  • Invest in 70+ cryptocurrencies and 3,000+ other assets including stocks and precious metals.

  • 0% commission on stocks - buy in bulk or just a fraction from as little as $10.

  • Copy top-performing traders in real time, automatically.

  • Regulated by financial authorities including FCA and FINRA.

2.8 Million Users
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk. eToro USA LLC does not offer CFDs, only real Crypto assets available. Don’t invest unless you’re prepared to lose all the money you invest.

Read Next:

Weekly Finance Digest

By subscribing you agree with Finbold T&C’s & Privacy Policy

Related posts